• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Tuesday, September 26, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

A step towards precision oncology for patients with metastatic urothelial carcinoma

Bioengineer by Bioengineer
December 30, 2022
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Bonn, December 30, 2022 – Dr. Niklas Klümper, resident at the Clinic for Urology and working group leader at the Institute for Experimental Oncology at the University Hospital Bonn (UKB), was awarded the C. E. Alken Prize in recognition of his outstanding scientific uro-oncological work. The 30 -year-old is investigating which patients with metastatic bladder cancer benefit from a new oncological form of therapy, the antibody-drug conjugates, in order to be able to use these promising drugs efficiently. His new findings were published this December in the renowned oncology journal Clinical Cancer Research.

Portrait Dr. Niklas Klümper

Credit: University Hospital Bonn (UKB)

Bonn, December 30, 2022 – Dr. Niklas Klümper, resident at the Clinic for Urology and working group leader at the Institute for Experimental Oncology at the University Hospital Bonn (UKB), was awarded the C. E. Alken Prize in recognition of his outstanding scientific uro-oncological work. The 30 -year-old is investigating which patients with metastatic bladder cancer benefit from a new oncological form of therapy, the antibody-drug conjugates, in order to be able to use these promising drugs efficiently. His new findings were published this December in the renowned oncology journal Clinical Cancer Research.

 

Chemotherapies used to treat aggressive advanced and metastatic urothelial carcinoma are often associated with many side effects. Recently, a new class of drugs, called antibody-drug conjugates, have been approved for patients with metastatic urothelial carcinoma. Antibody-drug conjugates consist of an antibody directed against the tumour cell surface conjugated with a highly toxic chemotherapeutic agent. This combines the selectivity of targeted antibody therapy with the cytotoxic potential of conventional chemotherapy, representing an innovative and new oncological therapeutic approach.

 

Use of antibody-drug conjugates

The Department of Urology at the UKB is also using this new drug to treat patients with metastatic urothelial carcinoma. “Enfortumab vedotin is the first approved antibody-drug conjugate and a very promising drug for the treatment of patients with metastatic urothelial carcinoma. However, we still understand little about who really benefits from this therapy, which can also cause severe side effects such as skin irritation or nerve disorders”, says Dr. Niklas Klümper, assistant physician at the Clinic for Urology at the UKB.

 

Targeted therapy does not reach all tumour cells

“We were able to show for the first time that the surface molecule for the targeted delivery of the chemotherapeutic agent in metastatic urothelial carcinoma is often decreased or absent. Lack of this surface structure, which can be detected by conventional immunohistochemistry, is associated with resistance to enfortumab vedotin, so these patients may be better treated with alternative therapies. Our work is therefore a step towards precision oncology for patients with metastatic urothelial carcinoma”, says Dr Klümper. His goal is to ensure that these potentially toxic drugs are only used for patients who can also benefit from the therapy.

 

Award for outstanding research

For his highly relevant findings for more precise therapy of urological tumour patients, Dr. Klümper was awarded the prestigious C. E. Alken Prize in November 2022. The C. E. Alken Foundation promotes clinical and experimental research in urology by awarding an annual prize for outstanding scientific work to excellent German-speaking researchers who have made a significant contribution to the field of urology. “This award is of outstanding importance in the urology field. The fact that Dr. Klümper receives this award as a young resident is special and speaks once again for his significant and highly innovative research into the therapy of bladder cancer,” says Prof Manuel Ritter, Director of the Clinic for Urology and Paediatric Urology at the UKB.

 

Dr. Klümpers’ experiences with the new drug, which could be highly relevant for treatment, are shared with a network of other university hospitals and clinics as part of the studies, so that they reach as many patients as possible as a therapy optimisation.

 

Publication:

Niklas Klümper, et al, “Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance.“

Clinical Cancer Research: https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-22-1764/711754/Membranous-NECTIN-4-expression-frequently

 



Journal

Clinical Cancer Research

DOI

10.1158/1078-0432

Article Title

Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance

Article Publication Date

19-Dec-2022

Share12Tweet8Share2ShareShareShare2

Related Posts

Figure 4

Four novel receptors may link endometrial cancer to PCOS

September 25, 2023
Wei Wang

UArizona Cancer Center researchers develop new way to target cancer cells

September 25, 2023

Insilico Medicine and University of Cambridge present new approach to discover targets for Alzheimer’s and other diseases with protein phase separation

September 25, 2023

People with long COVID have distinct hormonal and immune differences from those without this condition

September 25, 2023

POPULAR NEWS

  • blank

    Microbe Computers

    59 shares
    Share 24 Tweet 15
  • A pioneering study from Politecnico di Milano sheds light on one of the still poorly understood aspects of cancer

    35 shares
    Share 14 Tweet 9
  • Fossil spines reveal deep sea’s past

    34 shares
    Share 14 Tweet 9
  • Scientists go ‘back to the future,’ create flies with ancient genes to study evolution

    75 shares
    Share 30 Tweet 19

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Why endangered wildlife needs AML law coverage and banks need to share IWT intelligence

NASA’s Interstellar Mapping and Acceleration Probe passes system integration review

National Science Foundation taps Worcester Polytechnic Institute fire protection expertise and resources for the Wildfire Interdisciplinary Research Center

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 57 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In